362 related articles for article (PubMed ID: 30224341)
21. Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Miwa K; Oki E; Emi Y; Saeki H; Kusumoto T; Akagi Y; Ogata Y; Samura H; Tokunaga S; Ishikawa H; Tanaka T; Sueyoshi S; Higashi H; Matsuda H; Touyama T; Maehara Y;
Int J Clin Oncol; 2016 Feb; 21(1):110-7. PubMed ID: 26037783
[TBL] [Abstract][Full Text] [Related]
22. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
[TBL] [Abstract][Full Text] [Related]
23. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
24. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
[TBL] [Abstract][Full Text] [Related]
25. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
[TBL] [Abstract][Full Text] [Related]
26. BATON-CRC: A Phase II Randomized Trial Comparing Tivozanib Plus mFOLFOX6 with Bevacizumab Plus mFOLFOX6 in Stage IV Metastatic Colorectal Cancer.
Benson AB; Kiss I; Bridgewater J; Eskens FA; Sasse C; Vossen S; Chen J; Van Sant C; Ball HA; Keating A; Krivoshik A
Clin Cancer Res; 2016 Oct; 22(20):5058-5067. PubMed ID: 27401244
[TBL] [Abstract][Full Text] [Related]
27. Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.
O'Neil BH; Cainap C; Van Cutsem E; Gorbunova V; Karapetis CS; Berlin J; Goldberg RM; Qin Q; Qian J; Ricker JL; Fischer J; McKee MD; Carlson DM; Kim TW
Clin Colorectal Cancer; 2014 Sep; 13(3):156-163.e2. PubMed ID: 25066269
[TBL] [Abstract][Full Text] [Related]
28. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Shitara K; Yonesaka K; Denda T; Yamazaki K; Moriwaki T; Tsuda M; Takano T; Okuda H; Nishina T; Sakai K; Nishio K; Tokunaga S; Yamanaka T; Boku N; Hyodo I; Muro K
Cancer Sci; 2016 Dec; 107(12):1843-1850. PubMed ID: 27712015
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
30. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.
Van Cutsem E; Tabernero J; Lakomy R; Prenen H; Prausová J; Macarulla T; Ruff P; van Hazel GA; Moiseyenko V; Ferry D; McKendrick J; Polikoff J; Tellier A; Castan R; Allegra C
J Clin Oncol; 2012 Oct; 30(28):3499-506. PubMed ID: 22949147
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
[TBL] [Abstract][Full Text] [Related]
32. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer.
Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Chin K; Yamaguchi T
Drug Des Devel Ther; 2015; 9():1653-62. PubMed ID: 25834402
[TBL] [Abstract][Full Text] [Related]
33. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
34. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy.
Van Cutsem E; Joulain F; Hoff PM; Mitchell E; Ruff P; Lakomý R; Prausová J; Moiseyenko VM; van Hazel G; Cunningham D; Arnold D; Schmoll HJ; Ten Tije AJ; McKendrick J; Kröning H; Humblet Y; Grávalos C; Le-Guennec S; Andria M; Dochy E; Vishwanath RL; Macarulla T; Tabernero J
Target Oncol; 2016 Jun; 11(3):383-400. PubMed ID: 26706237
[TBL] [Abstract][Full Text] [Related]
35. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
36. Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.
Suenaga M; Matsusaka S; Ueno M; Yamamoto N; Shinozaki E; Mizunuma N; Yamaguchi T; Hatake K
Surg Today; 2011 Aug; 41(8):1067-74. PubMed ID: 21773895
[TBL] [Abstract][Full Text] [Related]
37. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Pinter T; Klippel Z; Cesas A; Croitoru A; Decaestecker J; Gibbs P; Hotko Y; Jassem J; Kurteva G; Novotny J; O'Reilly S; Salek T; Reiner M; Morrow PK; Choi MR; Whittaker S; Blanke C
Clin Colorectal Cancer; 2017 Jun; 16(2):103-114.e3. PubMed ID: 28038865
[TBL] [Abstract][Full Text] [Related]
38. Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Folprecht G; Pericay C; Saunders MP; Thomas A; Lopez Lopez R; Roh JK; Chistyakov V; Höhler T; Kim JS; Hofheinz RD; Ackland SP; Swinson D; Kopp M; Udovitsa D; Hall M; Iveson T; Vogel A; Zalcberg JR
Ann Oncol; 2016 Jul; 27(7):1273-9. PubMed ID: 27091810
[TBL] [Abstract][Full Text] [Related]
39. Aflibercept.
Ciombor KK; Berlin J; Chan E
Clin Cancer Res; 2013 Apr; 19(8):1920-5. PubMed ID: 23444216
[TBL] [Abstract][Full Text] [Related]
40. Effect of Early Adverse Events on Survival Outcomes of Patients with Metastatic Colorectal Cancer Treated with Ramucirumab.
Lim HH; Hopkins AM; Rowland A; Yuen HY; Karapetis CS; Sorich MJ
Target Oncol; 2019 Dec; 14(6):743-748. PubMed ID: 31676953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
